Intézmény

Mie University Hospital

Tsu, JapánHonlap

Más néven: Mie Prefecture medical school · 三重大学病院

82futó vizsgálat
27lezárt vizsgálat
5247publikáció (OpenAlex)

Futó vizsgálatok

Toboroz
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
NCT07855692· 2. fázis· Nagoya University· Forrás
Toboroz
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
NCT07734116· 1/2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Toboroz
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
NCT07766018· 2. fázis· Stemline Therapeutics, Inc.· Forrás
Toboroz
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
NCT07648030· 2. fázis· Takeda· Forrás
Fut, nem toboroz
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
NCT07666217· Intuitive Surgical· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Toboroz
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
NCT07605819· Cosomil, Inc.· Forrás
Toboroz
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802· 3. fázis· Takeda· Forrás
Toboroz
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094· 3. fázis· Genmab· Forrás
Toboroz
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996· 3. fázis· Sanofi· Forrás
Toboroz
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033· 3. fázis· PharmaEssentia· Forrás
Toboroz
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07023341· 3. fázis· Bayer· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Toboroz
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
NCT06682572· 2. fázis· Verastem, Inc.· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· 3. fázis· Ferring Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Toboroz
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· 3. fázis· Jazz Pharmaceuticals· Forrás
Fut, nem toboroz
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT06312176· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781· 3. fázis· Verastem, Inc.· Forrás
Toboroz
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06295692· 3. fázis· Janssen Pharmaceutical K.K.· Forrás
Fut, nem toboroz
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06023862· 2. fázis· Yonsei University· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359· 1. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· 3. fázis· Cytokinetics· Forrás
Fut, nem toboroz
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498· CathWorks Ltd.· Forrás

Showing 50 of 82.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Mieloproliferatív neopláziák4 toboroz
Petefészekrák4 toboroz
Pikkelysömör3 toboroz
Tripla negatív emlőrák3 toboroz
Zsírmáj (MASLD/MASH)3 toboroz
Áttétes emlőrák2 toboroz
Crohn-betegség2 toboroz
Méhtestrák2 toboroz
Alzheimer-kór1 toboroz
Arthritis psoriatica1 toboroz
Colitis ulcerosa1 toboroz
Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
Gyermekkori daganatok1 toboroz
Hasnyálmirigyrák1 toboroz
Hólyagrák1 toboroz
Liver cirrhosis1 toboroz
Prosztatarák1 toboroz
Szarkóma1 toboroz
Szívelégtelenség1 toboroz

Lezárt vizsgálatok

Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Alumis Inc· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06323356· 3. fázis· Takeda· Forrás
Lezárult
A Study to Evaluate P1101 in Japanese PV Patients
NCT06002490· 3. fázis· PharmaEssentia Japan K.K.· Forrás
Lezárult
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
NCT06023030· AbbVie· Forrás
Lezárult
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
NCT05791526· AbbVie· Forrás
Leállították
Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
NCT05368558· 3. fázis· AbbVie· Forrás
Leállították
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· 3. fázis· Incyte Corporation· Forrás
Lezárult
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT04777201· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT04673357· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT04630028· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
NCT04472598· 3. fázis· AbbVie· Forrás
Lezárult
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718· 3. fázis· Bayer· Forrás
Lezárult
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
NCT04435600· 3. fázis· AbbVie· Forrás
Lezárult
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
NCT04214028· AbbVie· Forrás
Lezárult
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
NCT03904693· 3. fázis· Actelion· Forrás
Lezárult
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
NCT04034095· Janssen Pharmaceutical K.K.· Forrás
Lezárult
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT03982394· AbbVie· Forrás
Lezárult
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03524092· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
NCT03518086· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
NCT03104374· 3. fázis· AbbVie· Forrás
Lezárult
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
NCT03104400· 3. fázis· AbbVie· Forrás
Lezárult
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
NCT03047395· 3. fázis· AbbVie· Forrás
Lezárult
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
NCT02906488· AbbVie· Forrás

Regiszterbeli névváltozatok (35)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

Mie University Hospital
Tsu, Mie-ken 514-8507
62 vizsgálat
Mie University Hospital
Mie, 514-8507
13 vizsgálat
Mie University Hospital
Tsu, Mie, Mie-ken 514-8507
3 vizsgálat
- NCT07286058Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
  Contact: Keiichi Yamanaka (principal investigator)
- NCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
  Contact: Keiichi Yamanaka (principal investigator)
- NCT06671496A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Mie University Hospital
Osaka
1 vizsgálat
- NCT05893498Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
Mie University Hospital /ID# 156317
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Mie University Hospital /ID# 162080
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03104400A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Mie University Hospital /ID# 162085
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03104374A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Mie University Hospital /ID# 164140
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT02906488Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
Mie University Hospital /ID# 203635
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
Mie University Hospital /ID# 203640
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Mie University Hospital /ID# 207253
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
Mie University Hospital /ID# 213387
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
Mie University Hospital /ID# 221664
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Mie University Hospital /ID# 221665
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
Mie University Hospital /ID# 230836
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT04435600A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Mie University Hospital /ID# 233864
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT04214028A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
Mie University Hospital /ID# 244710
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT05368558Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia
Mie University Hospital /ID# 251944
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Mie University Hospital /ID# 257011
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT05791526An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
Mie University Hospital /ID# 262656
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06023030An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Mie University Hospital /ID# 263008
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT04862286Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Mie University Hospital - Investigational Site Number : 3920009
Tsu, 514-8507
1 vizsgálat
- NCT07184996An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Mie University Hospital (Site 0615)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06456346Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Mie University Hospital (Site 0737)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  Contact: Study Coordinator
Mie University Hospital (Site 2312)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
Mie University Hospital (Site 2483)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Toll Free Number
Mie University Hospital (Site 2838)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Mie University Hospital (Site 3210)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
  Contact: Study Coordinator
Mie University Hospital (Site 3216)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  Contact: Study Coordinator
Mie University Hospital (Site 3405)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  Contact: Toll Free Number
Mie University Hospital (Site 3423)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  Contact: Study Coordinator
Mie University Hospital (Site 3615)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Mie University Hospital (Site 5109)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
Mie University Hospital (Site 9011)
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  Contact: Study Coordinator
The Mie University Hospital
Tsu, Mie-ken 514-8507
1 vizsgálat
- NCT06072781A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
  Contact: Eiji Kondo

Intézményadatok: ROR 01v9g9c07 (CC0-1.0)Frissítve: 2026. nov. 3.

Hibát jelzek